Pharmacokinetics interaction study of ^99mTc-glutathione radiopharmaceutical with doxorubicin in mice (mus musculus)

Abstract

The use of radiopharmaceuticals for cancer diagnosis and therapy is increasing. The radiopharmaceutical is also used to monitor the progress of a disease and determine the appropriate treatment. However, the use of radiopharmaceuticals needs to pay attention to the alteration in pharmacokinetics, pharmacology, and toxicity that are influenced by the drugs consumed by patients. Interaction between drugs with radiopharmaceuticals will cause alteration in pharmacokinetic effects. Therefore, this study aimed to determine the pharmacokinetic interaction of “-Tc-Glutathione radiopharmaceuticals with doxorubicin cancer drug in mice (Mus musculus). The pharmacokinetic studies were performed using four groups of animal model and each group consists of three rats. The groups were classified to normal mice without treatment of doxorubicin as normal mice control (I), normal mice treated with doxorubicin (II), cancer model mice without treatment of doxorubicin as cancer model mice control (III), and cancer model mice treated with doxorubicin (IV). The radioactivity in blood at a certain interval was then calculated to determine the distribution and elimination half-time. The distribution halftime of group I, II, III, and IV were 0.004±0.001, 0.0037±0.0001, 0.003±0.0001, and 0.0037±0.0001 hours, respectively, while the elimination half-time were 5.310±1.050, 10.7344±0.4692, 72.712±2.427, and 26.9320±7.8152 hours, respectively. The results of the T-test showed that there was a significant difference in elimination half-life of 99mTc-Glutathione between the treated group and the control group. These results indicate that administration of the doxorubicin before administration of 99m-Tc-Glutathione needs to be avoided because it can alter the elimination half-life of »-Tc-Glutathione. The results of this study are expected to provide benefits for clinicians in nuclear medicine to avoid the interpretation of incorrect diagnosis results, to achieve high-quality health service and will have a positive impact on the appropriate treatment for patients.